Solanbridge Group, Inc. (SLNX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSolanbridge Group, Inc. (SLNX) trades at $0.0001. Solanbridge Group, Inc. focuses on the production and sale of medical marijuana in Canada and CBD-infused products in the United States. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for SLNX: SLNX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Solanbridge Group, Inc. (SLNX) Healthcare & Pipeline Overview
Solanbridge Group, Inc. is a small-cap healthcare company focused on developing and selling medical marijuana in Canada and CBD-infused products in the US. Operating in a highly regulated and competitive market, the company faces challenges in scaling operations and achieving profitability.
What Is the Investment Thesis for SLNX?
Solanbridge Group, Inc. presents a speculative investment opportunity within the cannabis and CBD markets. The company's focus on medical marijuana in Canada and CBD products in the US offers exposure to potentially high-growth sectors. However, the company's small market capitalization ($0.00B), negative P/E ratio (-1.43), and high beta (-8.13) indicate significant risk. Key value drivers include successful product development, regulatory approvals, and market penetration. Growth catalysts involve expanding distribution networks and introducing new product lines. Potential risks include regulatory changes, competition, and the company's ability to secure funding for operations. Investors should carefully consider the company's financial position and the volatile nature of the cannabis industry before investing.
Based on FMP financials and quantitative analysis
SLNX Key Highlights
Solanbridge Group, Inc. operates in the medical marijuana and CBD-infused products market.
- The company focuses on production and sales in Nova Scotia, Canada, and Nevada, California, and Colorado.
- Solanbridge Group, Inc. has a market capitalization of $0.00B, indicating a small-cap company.
- The company's P/E ratio is -1.43, suggesting it is not currently profitable.
- The company's beta is -8.13, indicating high volatility and a negative correlation with the market.
Who Are SLNX's Competitors?
SLNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SLNX's Key Strengths?
Focus on high-growth cannabis and CBD markets.
- Operations in both Canada and the US.
- Potential for product diversification.
What Are SLNX's Weaknesses?
Small market capitalization and limited financial resources.
- Negative P/E ratio indicates lack of profitability.
- High beta suggests significant volatility.
What Are the Key Risks for SLNX?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Changes in government regulations regarding cannabis and CBD.
- Intense competition from larger companies.
- Limited financial resources and lack of profitability.
- High volatility and speculative nature of the stock.
- Negative beta indicates potential underperformance during market downturns.
What Threats Does SLNX Face?
- Intense competition from larger companies.
- Changing regulatory landscape.
- Potential shifts in consumer preferences.
What Are SLNX's Competitive Advantages?
- Geographic focus in specific regional markets.
- Early mover advantage in emerging cannabis and CBD markets.
- Proprietary formulations for CBD-infused products.
What Does SLNX Do?
Founded in 2000 and headquartered in The Woodlands, Texas, Solanbridge Group, Inc. is a healthcare company operating within the specialty and generic drug manufacturing sector. The company's primary focus is on the production and distribution of medical marijuana in Nova Scotia, Canada, and the development and sale of CBD-infused products in Nevada, California, and Colorado. Solanbridge aims to capitalize on the growing demand for cannabis and CBD products, targeting specific regional markets with tailored offerings. The company's strategy involves navigating the complex regulatory environments in both the US and Canada to establish a foothold in these emerging markets. Solanbridge faces competition from both established pharmaceutical companies and smaller cannabis-focused businesses. Its success hinges on its ability to secure necessary licenses, develop effective products, and build a strong distribution network. The company's operations are currently concentrated in North America, with potential for future expansion into other regions as regulations evolve.
What Products and Services Does SLNX Offer?
- Produces medical marijuana in Nova Scotia, Canada.
- Develops and sells CBD-infused products in Nevada.
- Develops and sells CBD-infused products in California.
- Develops and sells CBD-infused products in Colorado.
- Aims to capitalize on the growing demand for cannabis and CBD products.
- Navigates complex regulatory environments in the US and Canada.
How Does SLNX Make Money?
- Production and sale of medical marijuana in Canada.
- Development and sale of CBD-infused products in the US.
- Revenue generation through direct sales and distribution agreements.
What Industry Does SLNX Operate In?
Solanbridge Group, Inc. operates within the rapidly evolving cannabis and CBD industry. The market is characterized by increasing legalization, growing consumer demand, and intense competition. Solanbridge competes with other cannabis producers, pharmaceutical companies, and CBD product manufacturers. The company's success depends on its ability to navigate regulatory hurdles, develop innovative products, and establish a strong brand presence. The industry is also subject to changing consumer preferences and potential shifts in government policies.
Who Are SLNX's Key Customers?
- Patients in Canada seeking medical marijuana.
- Consumers in the US interested in CBD-infused products.
- Retailers and distributors of cannabis and CBD products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Solanbridge Group, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Solanbridge Group, Inc. stands at 118.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -14.2%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Solanbridge Group, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Lakewood, US. The company is led by CEO David J. Cutler. SLNX has traded publicly since 2007.
SLNX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SLNX Latest News
No recent news available for SLNX.
SLNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SLNX.
Price Targets
Wall Street price target analysis for SLNX.
SLNX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SLNX; grades run from A+ (80-100) to F (below 30).
Leadership: David J. Cutler
CEO
David J. Cutler serves as the CEO of Solanbridge Group, Inc. While detailed background information is limited, his role involves leading the company's strategic direction, overseeing operations, and managing relationships with stakeholders. He is responsible for guiding Solanbridge through the evolving cannabis and CBD markets, navigating regulatory challenges, and driving growth initiatives. His leadership is crucial for the company's success in a competitive industry.
Track Record: Information regarding David J. Cutler's specific achievements and milestones at Solanbridge Group, Inc. is not readily available. His tenure is focused on establishing the company's presence in the medical marijuana and CBD markets, securing necessary licenses, and developing a product portfolio. The company's progress under his leadership will be critical for future growth and investor confidence.
SLNX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Solanbridge Group, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and may not be current in their reporting obligations. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Increased price volatility.
- Potential for delisting or suspension of trading.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the OTC market and the company's specific circumstances.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Company's operational history since 2000.
- Focus on regulated markets (medical marijuana in Canada, CBD in the US).
- Presence of a CEO (David J. Cutler).
Solanbridge Group, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about SLNX stock?
As of 2026-03-16, there is no readily available analyst coverage or consensus on Solanbridge Group, Inc. (SLNX) due to its small market capitalization and OTC listing. Key valuation metrics, such as revenue projections and earnings estimates, are not widely tracked by analysts.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC status.